N@N

Cubist Pharmaceuticals Appoints Charles Laranjeira as Senior Vice President, Technical Operations

^{Published on 2011-06-27 13:10:33 - Market Wire}
 

LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced that Charles Laranjeira has joined the company as Senior Vice President of Technical Operations. Mr. Laranjeira oversees all facets of Cubista™s technical operations, including global manufacturing, quality, supply chain, and distribution. He reports to Robert Perez, Cubista™s Chief Operating Officer.

"Chuck combines broad and diverse international experience with an outstanding track record of building and leading successful global teams. I am confident that his vast experience and strong leadership will be instrumental as Cubist expands to become a global acute care leader in the years ahead."

Mr. Laranjeira comes to Cubist from Bristol-Myers Squibb (BMS) where he developed considerable expertise in global industrial operations management, including international pharmaceutical manufacturing. Most recently, he served as Vice President of Latin America, Asia Pacific & Japan, where he was responsible for regional operations management and product supply management to all markets within those regions. Prior to that position, he was Vice President of Asia Pacific and Japan, based in Singapore, and Vice President & General Manager, based in Puerto Rico. Mr. Laranjeiraa™s earlier positions with BMS include various roles of increasing responsibilities in technical operations, manufacturing, and industrial engineering in Spain, Australia, and the United States.

aWe are delighted to welcome Chuck Laranjeira to Cubist during this transformational year for the company,a said Mr. Perez. aChuck combines broad and diverse international experience with an outstanding track record of building and leading successful global teams. I am confident that his vast experience and strong leadership will be instrumental as Cubist expands to become a global acute care leader in the years ahead.a

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides, and has an agreement with Optimer Pharmaceuticals, Inc. to co-promote Optimera™s drug, DIFICIDa", in the U.S. as a treatment of Clostridium difficile infections. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

DIFICID is a trademark of Optimer Pharmaceuticals, Inc.